1921
Volume 104, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The efficacy and safety of hydroxychloroquine (HCQ) for the prevention and treatment of COVID-19 has received great attention, and most notably, the enthusiasm for HCQ has been one of politicization rather than science. Laboratory studies and case series published early in the pandemic supported its efficacy. The scientific community raced to conduct observational and randomized evaluations of the drug in all stages of the disease, including prophylaxis, early treatment, and advanced disease. Yet a divisive media response affected recruitment, funding, and subsequent enthusiasm for continuing scientific investigations. Of the more than 300 HCQ trials registered, fewer than 50% report having recruited any patients, and most trials might fail to achieve any useful portions of their intended sample size. Multiple observational studies and two large randomized trials have demonstrated HCQ does not offer efficacy against COVID-19 in hospitalized patients. Prophylaxis studies and early treatment studies provided heterogeneous results and are plagued by low event rates and poor study outcome monitoring. Emerging high-quality evaluations of prophylaxis and early treatment do not support a role for HCQ in these populations. The story of HCQ for COVID-19 has followed a pattern of initial enthusiasm supported by poor quality evidence, followed by disappointment based on more rigorous evaluations. The experience of HCQ in the COVID-19 era calls for the depoliticization of science away from media glare.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-1320
2020-11-24
2021-01-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/104/1/tpmd201320.html?itemId=/content/journals/10.4269/ajtmh.20-1320&mimeType=html&fmt=ahah

References

  1. Beigel JH et al., 2020. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med (Epub ahead of print). doi: 10.1056/NEJMoa2007764.
    [Google Scholar]
  2. Horby P et al., 2020. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med (Epub ahead of print). doi: 0.1056/NEJMoa2021436.
    [Google Scholar]
  3. Sinha N, Balayla G, 2020. Hydroxychloroquine and COVID-19. Postgrad Med J 96: 550555.
    [Google Scholar]
  4. Yao X et al., 2020. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71: 732739.
    [Google Scholar]
  5. Gautret P et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56: 105949.
    [Google Scholar]
  6. Intson K, Kumar S, Botta A, Neckles R, Leung C, Jawaid A, 2020. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19. Swiss Med Wkly 150: w20262.
    [Google Scholar]
  7. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N, 2020. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50: 384.
    [Google Scholar]
  8. Piszczatoski CR, Powell J, 2020. Emergency authorization of chloroquine and hydroxychloroquine for treatment of COVID-19. Ann Pharmacother 54: 827831.
    [Google Scholar]
  9. Geleris J et al., 2020. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 382: 24112418.
    [Google Scholar]
  10. Million M et al., 2020. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 35: 101738.
    [Google Scholar]
  11. Rosenberg ES et al., 2020. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 323: 24932502.
    [Google Scholar]
  12. Rodrigo C, Fernando SD, Rajapakse S, 2020. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clin Microbiol Infect 26: 979987.
    [Google Scholar]
  13. Ramireddy A et al., 2020. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for QT interval monitoring. J Am Heart Assoc 9: e017144.
    [Google Scholar]
  14. Nina PB, Dash AP, 2020. Hydroxychloroquine as prophylaxis or treatment for COVID-19: what does the evidence say? Indian J Public Health 64 (Supplement): S125S127.
    [Google Scholar]
  15. Das S, Bhowmick S, Tiwari S, Sen S, 2020. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19). Clin Drug Investig 40: 591601.
    [Google Scholar]
  16. Mehra MR, Desai SS, Ruschitzka F, Patel AN, 2020. RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (Epub ahead of print, 22 May 2020). doi: 10.1016/S0140-6736(20)31180-6.
    [Google Scholar]
  17. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC, 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. Faseb J 34: 60276037.
    [Google Scholar]
  18. Park JJH, Decloedt EH, Rayner CR, Cotton M, Mills EJ, 2020. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. Lancet Global Health 8: e1249e1250.
    [Google Scholar]
  19. Randomise Evaluation of COVID-19 Therapy, 2020. Statement from the Chief Investigators of the Randomised Evaluation of COVID-19 thERapY (RECOVERY) Trial on Hydroxychloroquine, June 5, 2020. Available at: https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf.
    [Google Scholar]
  20. MORU Tropical Health Network, 2020. COPCOV Trial. Available at: https://www.copcov.org. Accessed October 28, 2020.
    [Google Scholar]
  21. clinicaltrials.gov, 2020. Crown Coronation: COVID-19 Research Outcomes Worldwide Network for Coronavirus Prevention (CROWN CORONA). Available at: https://clinicaltrials.gov/ct2/show/NCT04333732.
    [Google Scholar]
  22. Pan H, 2020. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv. doi: 2020.2010.2015.20209817.
    [Google Scholar]
  23. US Food and Drug Administration, 2020. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.
    [Google Scholar]
  24. Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A, 2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Rev Anti Infect Ther 112.
    [Google Scholar]
  25. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M, 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6: 16.
    [Google Scholar]
  26. Cohen MS, 2020. Hydroxychloroquine for the prevention of COVID-19 - searching for evidence. N Engl J Med 383: 585586.
    [Google Scholar]
  27. Garcia-Albeniz X, Del Amo J, Polo R, Morales Asencio JM, Hernan MA, 2020. Brief communication: a meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. medRxiv. doi: 2020.2009.2029.20203869.
    [Google Scholar]
  28. Rajasingham R et al., 2020. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. medRxiv. doi: 2020.2009.2018.20197327.
    [Google Scholar]
  29. Cytel Inc, 2020. COVID-19 Response: New Opportunities and Implications for the Future of Drug Development in Emerging Economies. Available at: https://www.cytel.com/covid-19-virtual-panel-registration-global-health.
    [Google Scholar]
  30. clinicaltrials.gov, 2020. Treatment for COVID-19 in High-Risk Adult Outpatients (NCT04354428). Available at: https://clinicaltrials.gov/ct2/show/NCT04354428.
    [Google Scholar]
  31. Abena PM et al., 2020. Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg 102: 11841188.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-1320
Loading
/content/journals/10.4269/ajtmh.20-1320
Loading

Data & Media loading...

  • Received : 08 Oct 2020
  • Accepted : 06 Nov 2020
  • Published online : 24 Nov 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error